| Lakeland Rehab And Healthcare Center | |
| 500 N Williams St, Angola, Indiana 46703 | |
| (260) 665-2161 | |
| Name | Lakeland Rehab And Healthcare Center |
|---|---|
| Location | 500 N Williams St, Angola, Indiana |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 75 |
| Occupancy Rate | 52.13% |
| Medicare ID (CCN) | 155596 |
| Legal Business Name | Henry County Memorial Hospital |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1265911630 |
| Organization Name | APERION CARE ANGOLA LLC |
| Doing Business As | APERION CARE ANGOLA |
| Address | 500 Williams St, Angola, IN 46703 |
| Phone Number | 260-665-2161 |
News Archive
Researchers in the US recently infected a series of human lung and head/neck cancer cell lines with SARS-CoV-2 that expressed varying levels of ACE2 and the TMPRSS2 protease to reassess their role in viral entrance.
Celgene International Sàrl announced that investigational data evaluating combination therapy with REVLIMID (lenalidomide) and rituximab in patients with indolent non-Hodgkin's lymphoma (NHL) were presented during the 51st American Society of Hematology's annual meeting in New Orleans, LA.
Galectin Therapeutics, the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced metastatic melanoma.
Immunotherapy using monoclonal antibodies is a promising treatment strategy, and it might now be within reach: American scientists have successfully prepared an oligosaccharide enterobacterial antigen for which a monoclonal antibody has been developed. The study is published in the journal Angewandte Chemie.
› Verified 2 days ago
| NPI Number | 1962490649 |
| Organization Name | HENRY COUNTY MEMORIAL HOSPITAL |
| Doing Business As | APERION CARE ANGOLA |
| Address | 500 Williams St, Angola, IN 46703 |
| Phone Number | 260-665-2161 |
News Archive
Researchers in the US recently infected a series of human lung and head/neck cancer cell lines with SARS-CoV-2 that expressed varying levels of ACE2 and the TMPRSS2 protease to reassess their role in viral entrance.
Celgene International Sàrl announced that investigational data evaluating combination therapy with REVLIMID (lenalidomide) and rituximab in patients with indolent non-Hodgkin's lymphoma (NHL) were presented during the 51st American Society of Hematology's annual meeting in New Orleans, LA.
Galectin Therapeutics, the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced metastatic melanoma.
Immunotherapy using monoclonal antibodies is a promising treatment strategy, and it might now be within reach: American scientists have successfully prepared an oligosaccharide enterobacterial antigen for which a monoclonal antibody has been developed. The study is published in the journal Angewandte Chemie.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Researchers in the US recently infected a series of human lung and head/neck cancer cell lines with SARS-CoV-2 that expressed varying levels of ACE2 and the TMPRSS2 protease to reassess their role in viral entrance.
Celgene International Sàrl announced that investigational data evaluating combination therapy with REVLIMID (lenalidomide) and rituximab in patients with indolent non-Hodgkin's lymphoma (NHL) were presented during the 51st American Society of Hematology's annual meeting in New Orleans, LA.
Galectin Therapeutics, the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced metastatic melanoma.
Immunotherapy using monoclonal antibodies is a promising treatment strategy, and it might now be within reach: American scientists have successfully prepared an oligosaccharide enterobacterial antigen for which a monoclonal antibody has been developed. The study is published in the journal Angewandte Chemie.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 23.08 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 8.94 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 50 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.69 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 57.05 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.26 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 55.97 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 13.55 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 32.69 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.94 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 25.86 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 18.66 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 7.21 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 92.93 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 73.55 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 41.67 | 82.93 |
News Archive
Researchers in the US recently infected a series of human lung and head/neck cancer cell lines with SARS-CoV-2 that expressed varying levels of ACE2 and the TMPRSS2 protease to reassess their role in viral entrance.
Celgene International Sàrl announced that investigational data evaluating combination therapy with REVLIMID (lenalidomide) and rituximab in patients with indolent non-Hodgkin's lymphoma (NHL) were presented during the 51st American Society of Hematology's annual meeting in New Orleans, LA.
Galectin Therapeutics, the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced metastatic melanoma.
Immunotherapy using monoclonal antibodies is a promising treatment strategy, and it might now be within reach: American scientists have successfully prepared an oligosaccharide enterobacterial antigen for which a monoclonal antibody has been developed. The study is published in the journal Angewandte Chemie.
› Verified 2 days ago
Northern Lakes Nursing And Rehabilitation Center Location: 516 N Williams St, Angola, Indiana 46703 Phone: (260) 665-9467 | |
Lakeland Rehab And Healthcare Center Location: 500 N Williams St, Angola, Indiana 46703 Phone: (260) 665-2161 |